Google
PVLA — PALVELLA THERAPEUTICS, INC (Healthcare >> Biotechnology)
PVLA FAQ
What is PVLA's ROE?
PALVELLA THERAPEUTICS, INC reports a Return on Equity (ROE) of -21.22%.
What is PVLA's dividend yield?
PALVELLA THERAPEUTICS, INC offers a dividend yield of 0.00%.
What is PVLA's Deepscope Quality Score?
Deepscope rates PVLA's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PVLA?
Deepscope's AI Timing Score for PVLA is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does PVLA belong to?
PALVELLA THERAPEUTICS, INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 108.67
Price
-6.15
(-5.36%)
Day Change
|
|
|---|
PVLA, the overall quality is not good ( Quality = 15) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 108.67 |
| PBV / Sector |
7.13 / 4.63
|
| Earning Per Share | -3.24 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
25.48 M
GREAT
|
| Average 1W Daily Value |
35.48 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
47% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:07 |
| Symbol | PVLA |
| Name | PALVELLA THERAPEUTICS, INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 14.34 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,655.45 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 353 W. Lancaster Avenue, Wayne, PA, United States, 19087
Phone: 484 253 1461
Website: https://palvellatx.com
Sector: Healthcare >> Biotechnology
Description: Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
